Celldex Therapeutics Inc. (CLDX) Stock Price Down 2.4%
Celldex Therapeutics Inc. (NASDAQ:CLDX) was down 2.4% during trading on Wednesday . The company traded as low as $3.58 and last traded at $3.60, with a volume of 1,113,057 shares traded. The stock had previously closed at $3.69.
A number of equities research analysts have recently commented on CLDX shares. Jefferies Group raised their price target on Celldex Therapeutics to $5.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Wedbush reaffirmed a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 9th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, June 7th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Celldex Therapeutics presently has a consensus rating of “Hold” and an average target price of $10.75.
The company’s market capitalization is $374.03 million. The firm’s 50-day moving average price is $3.92 and its 200-day moving average price is $4.12.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/celldex-therapeutics-inc-cldx-stock-price-down-2-4.html
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02. The firm earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The company’s quarterly revenue was down 36.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share. Analysts predict that Celldex Therapeutics Inc. will post ($1.34) EPS for the current year.
Several hedge funds have recently modified their holdings of CLDX. Bellevue Group AG bought a new stake in shares of Celldex Therapeutics during the first quarter valued at approximately $605,000. A.R.T. Advisors LLC bought a new stake in shares of Celldex Therapeutics during the first quarter valued at approximately $3,446,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Celldex Therapeutics during the first quarter valued at approximately $521,000. Renaissance Technologies LLC bought a new stake in shares of Celldex Therapeutics during the first quarter valued at approximately $3,074,000. Finally, Geode Capital Management LLC increased its stake in shares of Celldex Therapeutics by 1.7% in the first quarter. Geode Capital Management LLC now owns 669,587 shares of the biopharmaceutical company’s stock valued at $2,531,000 after buying an additional 10,982 shares during the period. 78.41% of the stock is owned by hedge funds and other institutional investors.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.